TransMedics Group

YTD

ALL

Trade TransMedics Group 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TMDX

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform.

CEO

Waleed H. Hassanein

CEOWaleed H. Hassanein

Employees

898

Employees898

Headquarters

Andover, Massachusetts

HeadquartersAndover, Massachusetts

Founded

1998

Founded1998

Employees

898

Employees898

TMDX Key Statistics

Market cap

3.07B

Market cap3.07B

Price-Earnings ratio

23.04

Price-Earnings ratio23.04

Dividend yield

—

Dividend yield—

Average volume

1.21M

Average volume1.21M

High today

$88.87

High today$88.87

Low today

$88.87

Low today$88.87

Open price

$89.91

Open price$89.91

Volume

400.00

Volume400.00

52 Week high

$156.00

52 Week high$156.00

52 Week low

$60.11

52 Week low$60.11

Stock Snapshot

The current TransMedics Group(TMDX) stock price is $88.87, with a market capitalization of 3.07B. The stock trades at a price-to-earnings (P/E) ratio of 23.04.

As of 2026-08-17, TransMedics Group(TMDX) stock has fluctuated between $88.87 and $88.87. The current price stands at $88.87, placing the stock 0.0% above today's low and 0.0% off the high.

TransMedics Group(TMDX) shares are trading with a volume of 400, against a daily average of 1.21M.

During the past year, TransMedics Group(TMDX) stock moved between $60.11 at its lowest and $156.00 at its peak.

TMDX News

TipRanks 13h

TransMedics Group Ramps Growth With Record Earnings

Transmedics Group ((TMDX)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful inve...

Simply Wall St 18h

Is TransMedics Group Fairly Valued As Revenue Grew And 2026 Guidance Was Raised?

TransMedics Group (TMDX) is back in focus after reporting second quarter 2026 results that combined higher revenue with lower net income, along with a raised lo...

Simply Wall St 2d

TransMedics Group Is Up 5.6% After Raising 2026 Revenue Guidance Despite EPS Compression - simplywall.st

...

Analyst ratings

67%

of 12 ratings

Buy

66.7%

Hold

33.3%

Sell

More TMDX News

TipRanks 5d

TransMedics Buy Rating Reaffirmed as Analyst Maintains $95 Price Target on Robust Multi-Year Growth Outlook

TransMedics Group, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a...

People also own

Based on the portfolios of people who own TMDX. This list is generated using Robinhood data, and it’s not a recommendation.

MercadoLibre

Rocket Lab Corporation

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.